Back

CXCL13-CXCR5 Signaling in CD8⁺ T Cell Recruitment and Lymphoid Immune Organization in Clear Cell Renal Cell Carcinoma

Shapiro, D. D.; Nichols, K. D.; Lee, M. H.; Msaouel, P.; Li, Y.; Zong, Y.; Hu, R.; Huang, W.; Esbona, K.; Kinoshita, T.; Lotan, P.; Roadman, D. F.; Nkadori, E.; McGregor, S. M.; Beebe, D. J.; Kerr, S. C.; Capitini, C. M.; Abel, E. J.

2026-05-07 cancer biology
10.64898/2026.05.04.722710 bioRxiv
Show abstract

Clear cell renal cell carcinoma (ccRCC) exhibits heterogeneity in immune infiltration and clinical outcomes, but the mechanisms governing recruitment and organization of tumor-reactive CD8 T cells remain incompletely defined. We investigated the role of the CXCL13-CXCR5 axis in shaping CD8 T cell recruitment, differentiation, and immune organization in high-risk, non-metastatic ccRCC. Human tumor, plasma, and matched adjacent kidney specimens were analyzed using ELISA, quantitative PCR, migration assays, multiplex immunofluorescence, single-cell RNA sequencing, spatial transcriptomics, and a syngeneic mouse model. CXCL13 was among the most upregulated chemokines in ccRCC relative to matched normal kidney and was embedded within a CD8 T cell-associated inflammatory transcriptional program. In transwell and microphysiological system (MPS) assays, CXCL13 promoted CD8 T cell migration, enriched CXCR5 cells among migrating CD8 T cells and showed reduced migration after CXCL13 or CXCR5 blockade. Single-cell analyses identified CXCR5 expression within stem-like CD8 T cell states associated with TCF7 and IL7R, whereas CXCL13 associated with later cytotoxic/exhausted states along a continuous differentiation landscape. Spatial transcriptomics demonstrated that stem-like CD8 T cells localized within structured lymphoid aggregates enriched for B cells, coordinated CXCL13/CXCR5 expression, and signaling programs. In vivo, tumor-derived CXCL13 suppressed tumor growth, increased intratumoral CD8 T cell infiltration, and enriched CXCR5TCF1CD8 stem-like T cells. In human tumors, higher CXCL13 expression correlated with increased CXCR5CD8 T cell infiltration and improved recurrence-free survival. These findings identify CXCL13 as a regulator of immune recruitment and niche organization and support the CXCL13-CXCR5 axis as a biomarker and possible therapeutic target in ccRCC.

Matching journals

The top 9 journals account for 50% of the predicted probability mass.

1
Nature Communications
4913 papers in training set
Top 8%
17.3%
2
JCI Insight
241 papers in training set
Top 0.6%
6.3%
3
Genome Medicine
154 papers in training set
Top 1%
4.8%
4
Cell Reports Medicine
140 papers in training set
Top 0.7%
4.8%
5
Gastroenterology
40 papers in training set
Top 0.5%
4.2%
6
Cancer Research
116 papers in training set
Top 0.9%
3.5%
7
Cell Reports
1338 papers in training set
Top 15%
3.5%
8
Molecular Cancer Research
42 papers in training set
Top 0.1%
3.5%
9
Clinical Cancer Research
58 papers in training set
Top 0.5%
3.5%
50% of probability mass above
10
Cancer Cell
38 papers in training set
Top 0.6%
3.0%
11
Journal of Clinical Investigation
164 papers in training set
Top 2%
2.6%
12
Journal for ImmunoTherapy of Cancer
64 papers in training set
Top 0.4%
2.4%
13
eLife
5422 papers in training set
Top 36%
2.0%
14
Oncogene
76 papers in training set
Top 0.9%
1.9%
15
Scientific Reports
3102 papers in training set
Top 54%
1.9%
16
Cancer Discovery
61 papers in training set
Top 1%
1.7%
17
Journal of Experimental Medicine
106 papers in training set
Top 2%
1.7%
18
Cancers
200 papers in training set
Top 3%
1.7%
19
PLOS ONE
4510 papers in training set
Top 57%
1.5%
20
Cancer Letters
32 papers in training set
Top 0.4%
1.2%
21
Frontiers in Oncology
95 papers in training set
Top 3%
0.9%
22
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 40%
0.9%
23
Communications Biology
886 papers in training set
Top 17%
0.9%
24
Advanced Science
249 papers in training set
Top 17%
0.9%
25
Developmental Cell
168 papers in training set
Top 12%
0.7%
26
Cancer Immunology Research
34 papers in training set
Top 0.5%
0.7%
27
Molecular Cancer
14 papers in training set
Top 1%
0.7%
28
Frontiers in Immunology
586 papers in training set
Top 8%
0.7%
29
Neuro-Oncology
30 papers in training set
Top 0.8%
0.7%
30
The American Journal of Pathology
31 papers in training set
Top 0.7%
0.6%